The BROADEN (BROdmann Area 25 DEep brain Neuromodulation) study will evaluate the safety and effectiveness of deep brain stimulation in patients with depression for whom currently-available treatments are not effective.
Chris Chavez, president of St. Jude Medical’s ANS division, said: “We are hopeful that this trial will lead to the successful development of a sustainable therapy for those patients who have exhausted other treatment options.”